TNFRSF4 and neoplasm: SV expressing IL-12 combined with agonistic OX40 antibody changes the transcriptome and metabolic program of T cells, developing highly activated, terminally differentiated effector T cells, with enhanced tumor infiltration capacity that can overcome the repressive TME [1,12,13].